---
document_datetime: 2023-09-21 21:22:21
document_pages: 39
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/benefix-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: benefix-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 62.9555009
conversion_datetime: 2025-12-22 08:02:18.031276
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BeneFIX

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued² / amended on   | Product Information affected3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------|-------------------------------------|--------------------------------------------|---------------------------------|-----------|
| N/0173               | Minor change in labelling or package leaflet not connected with theSPC(Art.61.3Notification) | 12/10/2022                          |                                            | PL                              |           |
| IB/0172/G            | Thiswas an applicationfor agroupof variations.                                               | 07/10/2022                          | n/a                                        |                                 |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedfor all otherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII, Labelling,PL(Package Leaflet).

2A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics,annex II, labelling,package leaflet).The CD is issued within twomonths of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation(EU) No.712/2012, or within one yearfor other procedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | variation B.II.e.4.c-Change in shape or dimensions of the containeror closure(immediate packaging)-Sterile medicinalproducts B.II.e.4.c-Changeinshapeordimensionsofthe container or closure (immediate packaging) - Sterile medicinal products                            |            |            |    |                                |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|--------------------------------|
| IB/0171/G          | This was an applicationfor a group of variations. B.II.b.2.z -Change to importer,batch release arrangements andqualitycontrol testingof theFP- Other variation B.II.b.2.z-Change to importer,batch release arrangementsandqualitycontrol testingof theFP- Other variation | 06/07/2022 | n/a        |    |                                |
| N/0170             | Minorchangeinlabellingorpackageleafletnot connectedwiththeSPC(Art.61.3Notification)                                                                                                                                                                                       | 08/10/2021 |            | PL |                                |
| IB/0169            | B.I.b.1.b-Change in the specificationparameters and/or limits of anAS,starting material/intermediate/reagent-Tighteningof specification limits                                                                                                                            | 31/03/2021 | n/a        |    |                                |
| PSUSA/2183/ 202008 | PeriodicSafetyUpdateEUSingleassessment- nonacog alfa                                                                                                                                                                                                                      | 11/03/2021 | n/a        |    | PRACRecommendation-maintenance |
| N/0168             | Minorchangeinlabellingorpackageleafletnot connected with theSPC(Art.61.3 Notification)                                                                                                                                                                                    | 27/11/2020 | 22/09/2021 | PL |                                |

<div style=\"page-break-after: always\"></div>

|           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 17/09/2020   | 22/09/2021   | SmPC and PL   | II/0164 data                                                                        |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|-------------------------------------------------------------------------------------|
| IB/0166/G | Thiswas an applicationfor a groupof variations. B.II.z-Quality change-Finished product-Other variation B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier)-Deletion of a supplier B.II.e.7.a - Change in supplier of packaging components ordevices(whenmentioned in the dossier)-Deletionof asupplier B.II.e.7.a - Change in supplier of packaging componentsordevices(whenmentionedinthe dossier)-Deletion of a supplier B.II.e.7.a - Change in supplier of packaging componentsor devices(whenmentionedinthe dossier)-Deletion of asupplier B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier)-Deletion of a supplier B.II.e.7.z. - Change in supplier of packaging components ordevices(whenmentionedin the dossier)-Other variation | 10/09/2020   | n/a          |               | B.II.g.3-Deletionof an approvedchange managementprotocolrelatedtothefinishedproduct |
| IA/0165   | A.7 - Administrative change - Deletion of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 07/08/2020   | n/a          |               | manufacturingsites                                                                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| 11/0161/G   | Thiswas an applicationfor a groupof variations. B.I.a.2.a - Changes in the manufacturing process of theAS-Minor changein themanufacturingprocess of the AS B.I.a.2.a-Changes in the manufacturing process of theAS-Minor change in themanufacturingprocess of the AS B.I.a.2.c-Changes in the manufacturing process of theAS-Thechangereferstoa[-]substanceinthe manufactureofabiological/immunologicalsubstance whichmayhaveasignificantimpacton themedicinal productandisnotrelatedto aprotocol B.I.a.4.b -Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.c-Change toin-process tests orlimits appliedduringthemanufactureof theAS-Deletion of anon-significantin-processtest B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.c.1.a-Changein immediatepackaging of theAS -Qualitativeand/orquantitativecomposition B.I.d.1.c-Stability of AS-Change in the re-test   | 25/06/2020   | n/a   | period/storage period or storage conditions - Change to an approved stability protocol   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|------------------------------------------------------------------------------------------|
| 11/0163     | C.I.11.b - Introduction of, or change(s) to, the obligationsandconditionsofamarketing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 17/04/2020   | n/a   |                                                                                          |

<div style=\"page-break-after: always\"></div>

|                    | authorisation,includingtheRMP-Implementationof change(s)which require tobefurthersubstantiated bynewadditional data tobesubmittedby theMAH where significant assessment isrequired                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |     |                                |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------|
| PSUSA/2183/ 201908 | PeriodicSafetyUpdateEUSingle assessment- nonacog alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 12/03/2020 | n/a | PRACRecommendation-maintenance |
| 11/0160            | B.I.b.2.d-Change in test procedure forAS or startingmaterial/reagent/intermediate-Substantial changetoorreplacementofa biological/immunological/immunochemicaltest method or a method using a biological reagent for a biological AS                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 12/09/2019 | n/a |                                |
| 11/0156/G          | Thiswas an applicationfor a groupof variations. B.II.b.3.a-Change in the manufacturing process of the finished or intermediate product - Minor change inthemanufacturingprocess B.II.b.3.c -Change in the manufacturing process of the finished orintermediateproduct-The product is abiological/immunologicalmedicinal product and the changerequiresanassessmentofcomparability B.II.b.4.a-Changeinthebatchsize(includingbatch sizeranges)of the finished product-Upto10-fold comparedtothe originally approvedbatchsize B.II.e.6.b-Change in any part of the (primary) packagingmaterialnotincontactwith thefinished productformulation-Changethatdoesnotaffect theproductinformation | 02/05/2019 | n/a |                                |

<div style=\"page-break-after: always\"></div>

| IB/0159            | B.I.d.1.a.4-Stability of AS -Change in the re-test period/storage period - Extension or introduction of a re-testperiod/storageperiodsupportedbyreal time data                                                                                                                                                                                                                                                                        | 05/04/2019   | n/a   |                                |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|--------------------------------|
| IA/0158            | B.I.d.1.c-Stability of AS-Change in the re-test period/storage period or storage conditions-Change toan approvedstabilityprotocol                                                                                                                                                                                                                                                                                                     | 20/03/2019   | n/a   |                                |
| PSUSA/2183/ 201808 | Periodic Safety Update EU Single assessment - nonacog alfa                                                                                                                                                                                                                                                                                                                                                                            | 14/03/2019   | n/a   | PRACRecommendation-maintenance |
| IA/0157/G          | This was an application for a group of variations. B.II.e.7.a - Change in supplier of packaging components ordevices(whenmentioned in the dossier)-Deletion of a supplier B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier)-Deletion of a supplier B.II.e.7.b - Change in supplier of packaging components or devices(whenmentioned in the dossier)-Replacementoradditionofasupplier | 15/02/2019   | n/a   |                                |
| IB/0155/G          | This was an applicationfor a group of variations. A.7-Administrativechange-Deletionof manufacturing sites B.I.b.1.b-Change in the specification parameters and/or limits of an AS, starting                                                                                                                                                                                                                                           | 03/01/2019   | n/a   |                                |

<div style=\"page-break-after: always\"></div>

|                    | material/intermediate/reagent-Tightening of specification limits                                                                                                                                                                                                                                                |            |            |                        |                                |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------|
| IA/0154            | A.4-Administrative change-Change in the name and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateusedinthemanufactureoftheASor manufacturerofanovelexcipient                                                                                                    | 07/12/2018 | 19/11/2019 | Annex II               |                                |
| T/0152             | TransferofMarketingAuthorisation                                                                                                                                                                                                                                                                                | 11/07/2018 | 27/09/2018 | SmPC, Labelling and PL |                                |
| IB/0151/G          | Thiswasanapplicationforagroupofvariations. B.II1.2.a.1 - Change of specification(s) of a former nonEUPharmacopoeialsubstancetofullycomply with thePh.Eur.orwith a nationalpharmacopoeia of aMemberState-AS B.III.2.z-Change to comply with Ph.Eur.or with a nationalpharmacopoeiaofaMemberState-Other variation | 31/07/2018 | n/a        |                        |                                |
| IB/0150            | B.I.a.3.a -Change inbatch size(including batch size ranges)ofASorintermediate-Upto10-fold increase compared to the originally approved batch size                                                                                                                                                               | 06/07/2018 | n/a        |                        |                                |
| PSUSA/2183/ 201708 | PeriodicSafetyUpdateEUSingleassessment- nonacog alfa                                                                                                                                                                                                                                                            | 08/03/2018 | n/a        |                        | PRACRecommendation-maintenance |

<div style=\"page-break-after: always\"></div>

|           | A.7-Administrativechange-Deletionof                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 13/02/2018   | n/a   | IA/0149 manufacturing sites   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------|
| IB/0148   | B.1.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changesto a testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 17/01/2018   | n/a   |                               |
| I1/0146   | B.II.c.1.d-Changein thespecificationparameters and/orlimitsof anexcipient-Change outsidethe approved specifications limits range                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 26/10/2017   | n/a   |                               |
| IB/0145/G | This was an applicationfor a group of variations. B.I.a.1.f-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changestoquality control testing arrangementsfor theAS-replacement oradditionofa sitewhere batchcontrol/testingtakesplace B.I.a.1.f-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changes to a testprocedure(includingreplacement or addition) for the AS or a starting | 27/09/2017   | n/a   | material/intermediate         |

<div style=\"page-break-after: always\"></div>

| IA/0144            | A.6-Administrativechange-ChangeinATC Code/ATCVetCode                                                                                                                                                                                                                                               | 29/06/2017   | 07/06/2018   | SmPC                             |                                |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|--------------------------------|
| IA/0143            | B.I1.b.2.a-Change to importer,batch release arrangements and quality control testing of the FP - Replacement/additionofasitewherebatch control/testingtakesplace                                                                                                                                   | 23/06/2017   | n/a          |                                  |                                |
| IB/0142            | B.II.d.2.d-Change in testprocedure for the finished product-Otherchangesto a testprocedure (including replacement or addition)                                                                                                                                                                     | 17/05/2017   | n/a          |                                  |                                |
| X/0139             | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                         | 26/01/2017   | 22/03/2017   | SmPC, Labelling and PL           |                                |
| PSUSA/2183/ 201608 | PeriodicSafetyUpdateEUSingleassessment- nonacog alfa                                                                                                                                                                                                                                               | 09/03/2017   | n/a          |                                  | PRACRecommendation-maintenance |
| 11/0138            | B.II.g.2-Introduction of a post approval change managementprotocolrelated tothefinishedproduct                                                                                                                                                                                                     | 15/12/2016   | n/a          |                                  |                                |
| IB/0137/G          | This was an application for a group of variations. B.II.e.6.a-Change in any part of the (primary) packagingmaterialnotincontactwith thefinished productformulation-Change that affects the productinformation C.I.z-Changes(Safety/Efficacy)ofHuman and VeterinaryMedicinalProducts-Othervariation | 13/06/2016   | 21/10/2016   | SmPC, Annex II, Labelling and PL |                                |

<div style=\"page-break-after: always\"></div>

| IA/0136            | A.7-Administrativechange-Deletionof manufacturingsites                                                                                                                                                                                                                                                                                                                                                           | 16/05/2016   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                       |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2183/ 201508 | PeriodicSafetyUpdateEUSingleassessment- nonacog alfa                                                                                                                                                                                                                                                                                                                                                             | 17/03/2016   | n/a        |             | PRACRecommendation-maintenance                                                                                                                                                                                                                                                                                                                                        |
| IB/0135            | B.IV.1.z-Changeof ameasuring or administration device-Othervariation                                                                                                                                                                                                                                                                                                                                             | 08/01/2016   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                       |
| 11/0131            | Updateofsection5.1oftheSmPCwithinformation ononce-weaklyadministrationofBenefixbasedon two open label studies.TheRMPhasbeen updated accordingly.Additionally,section5.2hasbeen updated with new pharmacokinetic information. The MAH also introduced minor editorial changes throughout the PI. C.I.4 -Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 22/10/2015   | 21/10/2016 | SmPC        | In thisvariation theMAH updated theProduct Information withdatafromtwoopen-labelstudiesinwhichBeneFIX wasfoundtobesafelyadministered at100Iu/kgonce weekly.However,thehalf-life of theproduct and the limitedpharmacokineticstudydatafortheonceweekly regimendonotallowrecommending thisregimenin general for long term prophylaxis in severe haemophilia B patients. |
| I1/0133            | Updateof thesection4.8oftheSmPCinorderto revise adverse eventfrequenciesbased on\"all- causality\"and\"per patient”data set.Update of SmPC sections 4.1,4.2,4.4,4.5,4.7,4.8 and 4.9 and thecorresponding sectionsof thePL in line with thelatestrevisionoftheCoreSmPCforFactorIX Products.The RMPversion 8.1has been updated accordingly.                                                                           | 23/07/2015   | 20/08/2015 | SmPC and PL | In thisvariationtheMAHrevised thefrequenciesof23 adverse reactionslisted in section 4.8of theSmPC;as a result,21ofthetermsincreased infrequencycategory and 2ADRtermshadfrequencycategoriesthatremained unchanged.The changes inADRsfrequencywereprimarily drivenbythemethodologychangesandtheenlargementof the data-set, and do not represent a safety signal.       |

<div style=\"page-break-after: always\"></div>

|                    | new quality,preclinical, clinical orpharmacovigilance data                                                                                                                                                                                                                                                                                                                        |            |            |    |                                |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|--------------------------------|
| N/0132             | Minorchangeinlabellingorpackageleafletnot connectedwiththeSPC(Art.61.3Notification)                                                                                                                                                                                                                                                                                               | 24/06/2015 | 20/08/2015 | PL |                                |
| PSUSA/2183/ 201408 | PeriodicSafetyUpdateEUSingle assessment- nonacogalfa                                                                                                                                                                                                                                                                                                                              | 12/03/2015 | n/a        |    | PRACRecommendation-maintenance |
| 11/0126/G          | Thiswasanapplicationforagroupofvariations. Changestotheshelf-lifespecificationofthefinished productandtotheapprovedstabilityprotocolofthe finished product. B.II.d.1.e-Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.f.1.e-Stability of FP-Change to an approved stability protocol | 18/12/2014 | n/a        |    |                                |
| IA/0129            | A.7-Administrativechange-Deletionof manufacturing sites                                                                                                                                                                                                                                                                                                                           | 24/10/2014 | n/a        |    |                                |
| IB/0128/G          | Thiswas an applicationfor a groupof variations. B.II.b.1.f-Replacement or addition of a manufacturingsiteforpartorallofthe manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release,batchcontrol,andsecondarypackaging,for                                                                                                    | 16/10/2014 | n/a        |    |                                |

<div style=\"page-break-after: always\"></div>

|           | sterilemedicinalproducts(including those that are aseptically manufactured)excludingbiological/ immunologicalmedicinalproducts B.II.b.4.a -Change in the batch size(including batch size ranges) of the finished product - Up to 10-fold comparedtotheoriginallyapprovedbatchsize B.II.b.3.a-Change in the manufacturing process of the finished or intermediate product - Minor change in themanufacturingprocess                                                                          |            |     |                                |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------|
| IB/0127   | B.II.f.1.e-Stability of FP-Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                         | 14/08/2014 | n/a |                                |
| I1/0119/G | This was an application for a group of variations. B.II.b.5.d-Change to in-process tests or limits appliedduring themanufactureofthefinished product-Deletion of anin-processtestwhichmay have a significant effect on the overall quality of the finished product B.II.b.5.e -Change to in-process tests orlimits applied during the manufacture of the finished product-Widening of the approvedIPC limits,which may have a significant effect on overall quality of the finished product | 26/06/2014 | n/a |                                |
| PSUV/0121 | PeriodicSafetyUpdate                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 06/03/2014 | n/a | PRACRecommendation-maintenance |
| IA/0125   | B.II.e.7.b - Change in supplier of packaqing componentsordevices(whenmentionedinthe dossier)-Replacementoradditionofasupplier                                                                                                                                                                                                                                                                                                                                                               | 06/02/2014 | n/a |                                |

<div style=\"page-break-after: always\"></div>

| IA/0124   | A.4-Administrative change-Change in the name and/or addressof amanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateusedinthemanufactureoftheASor manufacturerofanovelexcipient                                                                                     | 03/02/2014   | 26/08/2014   | Annex II              |                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0122 | B.IV.1.a.1-Change of a measuring or administration device-Additionorreplacementofadevicewhichis notanintegratedpartof theprimarypackaging- Device with CE marking                                                                                                                                  | 12/12/2013   | n/a          |                       |                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0123   | B.I.b.2.a-Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure                                                                                                                                                                      | 02/12/2013   | n/a          |                       |                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0120   | B.II.e.7.b - Change in supplier of packaging components or devices(when mentioned in the dossier)-Replacement or addition of a supplier                                                                                                                                                            | 16/10/2013   | n/a          |                       |                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0118   | A.7-Administrative change-Deletion of manufacturing sites                                                                                                                                                                                                                                          | 23/09/2013   | n/a          |                       |                                                                                                                                                                                                                                                                                                                                                                                                                 |
| I1/0117   | Updateofsection4.8of theSmPCtoincludefour adverse drug reactions (laryngospasm, wheezing, tremor, and somnolence) in line with the company core datasheet.ThePackageLeafletwasproposed tobeupdatedaccordingly. Furthermore,thePI is beingbrought in line with the latest QRD template version 9.0. | 19/09/2013   | 26/08/2014   | SmPC, Annex II and PL | As a consequence of aninternal review,theMAH is correctinginconsistenciesregardingtheinformationon adverseDrugReactions(ADR)betweentheCoreData Sheet(CDS)andSummaryofProductCharacteristics (SmPC) of BeneFIX. Laryngospasm and wheezing (as a clinical sign of bronchospasm) were already listed in the PI butnotinsection4.8of theSmPC,tremor and somnolence, were reported in the pivotal studies and in the |

<div style=\"page-break-after: always\"></div>

|           | C.I.4 -Variations related to significant modifications of theSPCdueinparticular tonewquality,pre- clinical, clinical or pharmacovigilance data                                                                                                                                                                                                                 |            |            | post-marketing setting and have now been included in section 4.8of theSmPC.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------------------------------------------------------------------|
| N/0116    | Minor changeinlabelling orpackageleafletnot connectedwiththeSPC(Art.61.3Notification)                                                                                                                                                                                                                                                                          | 19/07/2013 | 26/08/2014 |                                                                               |
| 11/0112   | Additionalstoragesites. B.I.a.1.e-Change in themanufacturer ofASor of a startingmaterial/reagent/intermediateforAS-The change relates to a biological AS or a starting material [-1 used in the manufacture of a biological/immunologicalproduct                                                                                                               | 27/06/2013 | n/a        |                                                                               |
| IA/0115   | B.II.e.7.b-Change in supplier of packaging components or devices(when mentioned in the dossier)-Replacement or additionof a supplier                                                                                                                                                                                                                           | 17/04/2013 | n/a        |                                                                               |
| IA/0114/G | This was an applicationfor a group of variations. B.II.b.2.a-Change tobatch release arrangements andqualitycontrol testingoftheFP-Replacement oradditionofasitewherebatchcontrol/testing takes place B.II.b.2.a-Change tobatch release arrangements andqualitycontrol testingoftheFP-Replacement or addition of a site where batch control/testing takes place | 14/03/2013 | n/a        |                                                                               |
| 11/0111/G | This was an applicationfor a group of variations.                                                                                                                                                                                                                                                                                                              | 17/01/2013 | n/a        |                                                                               |

<div style=\"page-break-after: always\"></div>

| Additional testmethodsforfinishedproduct. B.II.d.2.c-Change in test procedure for the finished product - Replacement of a biological/ immunological/immunochemical testmethodor a methodusing abiologicalreagent B.II.d.2.d-Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d-Change in testprocedure for the finished product-Otherchanges to atestprocedure (including replacement or addition) B.II.d.2.z - Change in test procedure for the finished product-Othervariation   |            |     |           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| Thiswas an applicationfor a groupof variations. Introductionofalternativetestmethodsforthe active substance. B.I.b.2.d-Change in test procedure forAS or starting material/reagent/intermediate - Change (replacement)toabiological/immunological/ immunochemical test method or a method using a biologicalreagentforabiologicalAS B.1.b.2.e-Changein test procedure forAS or startingmaterial/reagent/intermediate-Other changesto a testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate                                | 17/01/2013 | n/a | I1/0110/G |

<div style=\"page-break-after: always\"></div>

|           | B.I.b.2.e - Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changes to a testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |                       |                                                                                                                                  |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------|
| 11/0108   | Update ofsections 4.2 and5.1of theSmPC to includeinformation supporting theuse ofBeneFIX in childrenlessthan6yearsofagefromStudy 3090A1-301-WWanddeletethestatementthat thereareinsufficientdata tosupport the useof BeneFIXin thispatientpopulation.Section5.2of the SmPCwasalsorevisedtoincludeadditional pharmacokineticsparametersin childrencoming froma popPKmodel.The MAH took the opportunity of thisvariation tobring thePI in line with thelatest versionoftheQRDtemplate(version8.2）in particular the terms and order in which SoC are presented in section 4.8 of the SmPC. Finally, the MAHupdated thecontactdetailsofrepresentatives in memberstates. C.I.6.a -Change(s) to therapeutic indication(s) - Additionofanewtherapeuticindicationor modificationofanapprovedone | 17/01/2013 | 18/02/2013 | SmPC, Annex II and PL | SeeScientificDiscussion H-139-VAR-II-108-en.                                                                                     |
| IG/0235/G | Thiswas an applicationfor a groupof variations. C.I.z-Changes(Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Othervariation C.I.9.b-Changes toan existingpharmacoviqilance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 06/12/2012 | n/a        |                       | C.I.z-Toreplace theDetailedDescription of the PharmacovigilanceSystem(DDPS)with the Pharmacovigilance System Master File (PSMF). |

<div style=\"page-break-after: always\"></div>

|           | system as described in the DDPS - Change in the contactdetailsoftheQPPV                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| X/0103    | Approval of new strength 3000IU/vial Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                       | 21/06/2012 | 23/08/2012 | SmPC, Labelling and PL | The new strength of 3000 IU is intended for the following approved indication: treatment and prophylaxis of bleeding inpatientswithhaemophiliaB(congenital factorIX deficiency).Thebenefixriskprofileforthe newstrength is the same as for the already approved ones.                                                                                                                    |
| R/0107    | Renewalofthemarketingauthorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                   | 24/05/2012 | 20/07/2012 |                        | BasedontheCHMPreviewofdataonquality,safetyand efficacy,including all variationsintroducedsince the marketing authorisation was granted, the CHMPconsiders byconsensusthattherisk-benefitbalanceofBeneFIXin thetreatmentandprophylaxisofbleedinginpatientswith haemophiliaB(congenitalfactorIXdeficiency)remains favourableandthereforerecommendstherenewalofthe marketing authorisation. |
| IG/0169/G | This was an application for a group of variations. C.I.9.e-Changestoanexistingpharmacovigilance system as described in the DDPS - Changes in the majorcontractual arrangementswithotherpersons or organisationsinvolvedinthefulfilment of pharmacovigilanceobligations anddescribedinthe DD C.I.9.h -Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) totheDDPSthatdoesnotimpactontheoperationof thepharmacovigilancesystem | 08/06/2012 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                          |
| I1/0102   | Change to active substance manufacturing process.                                                                                                                                                                                                                                                                                                                                                                                                                     | 15/03/2012 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|         | B.I.a.3.c - Change in batch size (including batch size ranges)of AS orintermediate-The change requires assessmentofthecomparabilityofa biological/immunological AS                                                                                                                      |            |            |                        |                   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------|
| 11/0101 | Alternative method for active substance batch release testing. B.I.b.2.d-Change in testprocedure forAS or starting material/reagent/intermediate - Change (replacement)toabiological/immunological/ immunochemical test method or a method using a biological reagentfor abiological AS | 15/03/2012 | n/a        |                        |                   |
|         | B.I.a.1.z-Change in the manufacturer ofASor of a starting material/reagent/intermediate for AS - Other                                                                                                                                                                                  | 14/02/2012 | n/a        |                        | IB/0106 variation |
|         | B.II.b.3.z-Change in the manufacturing process of thefinishedproduct-Other variation                                                                                                                                                                                                    | 23/11/2011 | n/a        |                        | IB/0105           |
| T/0100  | TransferofMarketingAuthorisation                                                                                                                                                                                                                                                        | 25/05/2011 | 23/06/2011 | SmPC, Labelling and PL |                   |
|         | Thiswas an applicationfor avariationfollowing a worksharingprocedureaccording toArticle20of CommissionRegulation(EC)No1234/2008. C.I.8.b-Introductionof a newPharmacovigilance system -which has been assessed by the relevant                                                          | 14/04/2011 | 31/05/2011 | Annex II               | WS/0117           |

<div style=\"page-break-after: always\"></div>

|           | NCA/EMAforanotherproductofthesameMAH                                                                                                                                                                                                                                                   |            |            |                                 |                                                                                                                                                                                                                                                                                                                              |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I1/0093   | Changetorawmaterialusedintheactivesubstance manufacturing process. B.I.a.1.e-ChangeinthemanufacturerofASorofa startingmaterial/reagent/intermediateforAS-The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunologicalproduct | 14/04/2011 | 02/05/2011 |                                 |                                                                                                                                                                                                                                                                                                                              |
| IB/0099   | B.II.f.1.d - Stability of FP - Change in storage conditions of thefinishedproductorthe diluted/reconstitutedproduct                                                                                                                                                                    | 30/03/2011 | n/a        | SmPC, Labelling and PL          |                                                                                                                                                                                                                                                                                                                              |
| IB/0098   | C.I.7.z-Deletion of formulation                                                                                                                                                                                                                                                        | 02/03/2011 | n/a        | SmPC,Annex II, Labelling and PL | DeletionoftheoriginalformulationofBenefix (presentations001,002 and003)whichwasreformulated and approved asline extension inJuly2007(presentations 004,005 and 007). TheMAH hasalsotaken the opportunitytoupdateAnnex IIBinlinewiththeproceduralannouncementfromOctober andNovember2010regardingthepharmacovigilance system. |
| 11/0088/G | Thiswas an applicationfor agroupof variations. Changes in the manufacturing process of the active substance. B.I.a.2.c-Changes in the manufacturing process of the AS-The change refers to a[-] substance in the                                                                       | 17/02/2011 | 01/03/2011 |                                 |                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|        | manufactureofabiological/immunological medicinal product and is not related to aprotocol B.I.a.3.c-Change in batch size (including batch size ranges)ofASorintermediate-Thechangerequires assessment of the comparability of a biological/immunological AS   |            |     |                        |           |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|-----------|
|        | B.I.a.4.f -Change to in-process tests or limits applied during the manufacture of the AS - Addition orreplacement of an in-process test as aresultof a safety orqualityissue                                                                                 | 25/01/2011 | n/a |                        | IB/0097   |
|        | Minor change in labelling or package leaflet not connected with theSPC(Art.61.3 Notification)                                                                                                                                                                | 16/11/2010 | n/a | Labelling              | N/0096    |
| N/0095 | Minor change in labelling or package leaflet not connectedwiththeSPC(Art.61.3Notification)                                                                                                                                                                   | 27/10/2010 | n/a | PL                     |           |
|        | B.II.f.1.b.1-Stability of FP-Extension of the shelf lifeof thefinishedproduct-Aspackagedforsale (supported byreal time data)                                                                                                                                 | 04/10/2010 | n/a |                        | IB/0094   |
|        | Thiswasanapplicationforagroupofvariations. To change the storage conditions of the finished product To change the stability protocol B.II.f.1.d - Stability of FP - Change in storage                                                                        | 13/08/2010 | n/a | SmPC, Labelling and PL | IB/0091/G |

<div style=\"page-break-after: always\"></div>

|         | B.II.f.1.z-Stability of FP-Change in the shelf-life or storageconditionsof thefinishedproduct-Other variation B.II.f.1.z-Stability of FP-Change in the shelf-life or storageconditionsof thefinishedproduct-Other variation   |            |            |                      |                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0092 | - To change the stability program of the acitve substance B.I.d.1.z-Stability of AS -Change in the re-test period/storage period or storage conditions - Other variation                                                      | 08/07/2010 | n/a        |                      |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| S/0084  | Annualre-assessment.                                                                                                                                                                                                          | 18/02/2010 | 05/05/2010 | SmPC,Annex II and PL | The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the Marketing AuthorisationHolder andhavingre-assessed the benefit/riskprofileofthemedicinalproduct,concludedthat thebenefit/riskremainsfavourableandsinceallspecific obligations have been fulfilled, there are no remaining grounds for the Marketing Authorisations to remain under exceptionalcircumstances. |
| 11/0083 | Amendmenttodrugsubstancemanufacture. Quality changes                                                                                                                                                                          | 22/04/2010 | 03/05/2010 |                      |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0090 | To change the currentpharmacopeial identification testby anotherpharmacopeial identification test. B.II.c.2.a-Change in test procedure for an excipient -Minorchangesto anapprovedtestprocedure                               | 08/04/2010 | n/a        |                      |                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| IA/0089/G   | Thiswas an applicationfor a group of variations. C.I.9.a-Changes to anexistingpharmacovigilance systemasdescribed in theDDPS-Changeinthe QPPV C.I.9.c-Changes to an existingpharmacovigilance system as described in the DDPS - Change of the back-upprocedureoftheQPPV C.I.9.e-Changes to an existingpharmacovigilance system as described in the DDPS - Changes in the majorcontractual arrangementswithotherpersons ororganisationsinvolvedinthefulfilment of pharmacovigilanceobligations anddescribed inthe DD C.I.9.g-Changes toanexistingpharmacovigilance system as described in the DDPS - Change of the site undertakingpharmacovigilanceactivities C.I.9.h-Changes to anexistingpharmacovigilance system as described in the DDPS - Other change(s) totheDDPS thatdoesnotimpactontheoperation of   | 08/04/2010   | n/a        | Annex II   | the pharmacovigilance system   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------|--------------------------------|
| N/0087      | Minorchangeinlabellingorpackageleafletnot connected with theSPC(Art.61.3Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 17/02/2010   | n/a        | PL         |                                |
| 11/0085     | Update of Module 3.2.S 2.3 Control of Starting Material and3.2.RRegional Information. Quality changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 21/01/2010   | 27/01/2010 |            |                                |

<div style=\"page-break-after: always\"></div>

| 11/0081   | Additional drugproductmanufacturer.                                          | 17/12/2009   | 20/01/2010   |                 | Additional drugproductmanufacturer.                                                                                                                                                                                                                                                                                                 |
|-----------|------------------------------------------------------------------------------|--------------|--------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0086   | IA_o5_Change in the name and/or addressof a manufacturerofthefinishedproduct | 09/12/2009   | n/a          | Annex II and PL |                                                                                                                                                                                                                                                                                                                                     |
| I1/0082   | UpdateofSummaryofProductCharacteristicsand PackageLeaflet                    | 24/09/2009   | 28/10/2009   | SmPC and PL     | Followingacaseofblurredvisionreportedinthe14th PeriodicSafetyUpdateReport(PSUR),theMAHreviewed its safety database and consequently proposed to update theProductInformation. Sections4.4and4.8oftheSPCwereupdatedtoadd \"blurredvision\"as anearlysymptomof ahypersensitivity reaction.ThePackageLeaflethasbeen updated accordingly. |
| 11/0079   | Changeindrug substance control assayand specification. Quality changes       | 24/09/2009   | 29/09/2009   |                 | Change in drug substance control assay andspecification.                                                                                                                                                                                                                                                                            |
| II/0075   | Changetodrugsubstancebatchreleaseandstability test method. Quality changes   | 25/06/2009   | 16/07/2009   |                 | Changetodrugsubstancebatchreleaseandstabilitytest method.                                                                                                                                                                                                                                                                           |
| II1/0077  | ChangestoQPPV Update ofDDPS(Pharmacovigilance)                               | 29/05/2009   | 30/06/2009   | Annex II and PL | Updateof theDetailedDescriptionofthe Pharmacovigilance System(DDPS)[Module 1.8.1]to reflect a change in theQualifiedPerson in theEEAfor Pharmacovigilance(QPpV).Other administrative and editorial changes are incorporated in this revised DDPS (version 2.1) as well as change in the UK local                                    |

<div style=\"page-break-after: always\"></div>

|         |                                                                                |            |            |                         | representative.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------|--------------------------------------------------------------------------------|------------|------------|-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11/0078 | Alternative testing site for one control test of drug product. Quality changes | 29/05/2009 | 16/06/2009 |                         | Alternativetestingsiteforonecontrol testofdrugproduct.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0080 | IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site     | 05/06/2009 | n/a        |                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| I1/0073 | UpdateofSummaryofProductCharacteristics, LabellingandPackageLeaflet            | 19/03/2009 | 22/04/2009 | SmPC,  Labelling and PL | The MAH proposed to update the SPC, PIL following a reviewofthepharmacovigilancedatabase,updateofthe ProductInformationinlinewiththecompanycore datasheetversion9.0andforlinguisticimprovement. Theagreed amendmentstotheProductInformation regarding substantial safety issues include: (1) theriskof thrombosisprimarilyinneonates together with the risk of administration via continuous infusion (non-approved method of administration) (section 4.4 and 4.8), (2) addition of\"bronchospasm\"and\"laryngospasm\"as symptoms of \"hypersensitivity reaction\" and in section 4.4. (3) andupdateof\"inadequate therapeuticresponse/ factorIX recovery\"in section 4.8. Furthermore,theCHMPagreedwithMAH toupdatethe section4.2oftheSPCregardingtheadministrationof BeneFIXbycontinuousinfusionbystating thatthisisnot an approved method of administering theproduct. Consequently continuous infusion is not recommended. |

<div style=\"page-break-after: always\"></div>

| S/0074   | Annual re-assessment.                                                                    | 18/12/2008   | 23/02/2009   | Annex II              | TheCHMP,havingreviewedtheevidenceofcompliance with the specific obligations submitted by the Marketing AuthorisationHolder andhavingre-assessed the benefit/riskprofileofthemedicinalproduct,recommends thatthemarketingauthorisationremainsunderexceptional circumstances. TheCHMPagreedwiththeamendmentofannexIIofthe PI,following thefulfillment of a specificobligation.   |
|----------|------------------------------------------------------------------------------------------|--------------|--------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11/0070  | Modification to the manufacturing process of the drug substance. Quality changes         | 25/09/2008   | 01/10/2008   |                       | Modification to the manufacturing process of the drug substance.                                                                                                                                                                                                                                                                                                               |
| 11/0069  | Quality changes                                                                          | 25/09/2008   | 01/10/2008   |                       |                                                                                                                                                                                                                                                                                                                                                                                |
| IA/0072  | IA_o9_Deletionofmanufacturingsite                                                        | 12/08/2008   | n/a          |                       |                                                                                                                                                                                                                                                                                                                                                                                |
| IA/0071  | IA_27_a_Change to test proc. of immediate packaging-minorchange toapprovedtest procedure | 07/05/2008   | n/a          |                       |                                                                                                                                                                                                                                                                                                                                                                                |
| 11/0068  | Quality changes                                                                          | 24/04/2008   | 28/04/2008   |                       |                                                                                                                                                                                                                                                                                                                                                                                |
| 11/0066  | Quality changes                                                                          | 21/02/2008   | 26/02/2008   |                       |                                                                                                                                                                                                                                                                                                                                                                                |
| S/0065   | Annualre-assessment.                                                                     | 13/12/2007   | 14/02/2008   | SmPC, Annex II and PL | Basedonthereviewofthe availableinformation,theCHMP isof theopinionthatthequality,safetyandefficacyof BeneFIXcontinuestobeadequatelyandsufficiently demonstratedandthereforeconsideredthatthe benefit/riskprofileofBeneFIXremainsunchangedinthe treatmentofhaemophiliaB.Nonetheless,sincethereare                                                                               |

<div style=\"page-break-after: always\"></div>

|         |                                                                          |            |            |                                  | stillspecificobligationswhichneedtobefulfilleditis recommended thatthemarketing authorisationofBeneFIX remainsunderexceptional circumstances.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------|--------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0067 | IA_O8_a_Change in BR/QC testing - repl./add. of batchcontrol/testingsite | 20/12/2007 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| I1/0064 | Update of or change(s) to the pharmaceutical documentation               | 13/12/2007 | 19/12/2007 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| R/0063  | Renewalof themarketing authorisation.                                    | 24/05/2007 | 07/08/2007 | SmPC, Annex II, Labelling and PL | BasedontheCHMPreviewoftheavailableinformationand on the basis of a re-evaluation of the benefit risk balance, the CHMP is of the opinion that the quality, safety and efficacyofthismedicinal productcontinues tobe adequatelyandsufficientlydemonstratedandtherefore consideredthatthebenefitriskprofileofBeneFIXcontinues tobefavourable. Further to the recent positive opinions granted to the extensionapplicationsEMEA/H/C/139/X/55andX/57, majorchangestotheformulationofBeneFIXaswell asa new higher strength are to be introduced on the market. Thesafetyprofileofthenewformulationneedstobe closelymonitored and asthere arestill ongoingspecific obligations, the CHMP recommends that the Marketing AuthorisationofBeneFIXremainsunderexceptional circumstances and thatone additionalfive-yearrenewal on the basis of pharmacovigilance grounds is required. |
| X/0057  | X-3-ii_Addition of new strength                                          | 24/05/2007 | 30/07/2007 | SmPC, Labelling and PL           | TheApplicanthassubmitted anextensionapplicationto the marketing authorisationfor anewstrength(20o0IU)of BeneFIXforthetreatmentandprophylaxisofbleedingin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|         |                                                       |            |            |                        | patientswithhaemophiliaB(congenital factorIX deficiency). Another extension application to the marketing authorisationfor a newformulationofBeneFIXwas also submitted and assessedsimultaneously. Based on the provided data on quality, non-clinical and clinical aspects,thebenefitrisk assessmentfor reformulatedBeneFIXisconsideredfavourable.                                                                                                                                              |
|---------|-------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| X/0055  | AnnexI_2.(d)Changeoradditionofanew pharmaceuticalform | 24/05/2007 | 30/07/2007 | SmPC, Labelling and PL | TheMAHhassubmittedanextensionapplicationtothe marketing authorisationforanewformulationofBeneFIX for thetreatment andprophylaxis of bleedinginpatients withhaemophiliaB (congenital factorIXdeficiency). Another extension application to the marketing authorisationforanewstrength(20o0IU)ofBeneFIXwas alsosubmitted and assessedsimultaneously. Basedon theprovideddata onquality,non-clinical and clinical aspects,thebenefit risk assessmentfor reformulatedBeneFIXisconsideredfavourable. |
| I1/0060 | Quality changes                                       | 22/03/2007 | 02/05/2007 | Annex II and PL        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 11/0059 | Quality changes                                       | 22/03/2007 | 02/04/2007 |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| S/0058  | Annual re-assessment.                                 | 14/12/2006 | 15/02/2007 | Annex II and PL        | TheMAHfulfilledoneof theirSpecificObligationsby completing anewclinical studywithBeneFIXin20 PreviouslyTreatedPatients(PTPs)accordingo theNotefor GuidanceonFVIII/FIXproductsCHMP/BPWG/1561/99. Based on the data submitted in this annual re-assessment,                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|         |                                                                                      |            |            |             | the product remains under exceptional circumstances.                      |
|---------|--------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------|
| IA/0062 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site             | 07/02/2007 | n/a        |             |                                                                           |
| I1/0052 | Quality changes                                                                      | 18/10/2006 | 24/10/2006 |             |                                                                           |
| 11/0051 | Quality changes                                                                      | 21/09/2006 | 28/09/2006 |             |                                                                           |
| II/0050 | Quality changes                                                                      | 21/09/2006 | 28/09/2006 |             |                                                                           |
| IA/0053 | IA_25_b_01_Change to comply withPh.- compliance with EU Ph.update-active substance   | 26/06/2006 | n/a        |             |                                                                           |
| IA/0056 | IA_16_b_Submission of new TSE certificate relating toactivesubstance-othersubstances | 22/05/2006 | n/a        |             |                                                                           |
| II/0049 | UpdateofSummaryofProductCharacteristicsand Package Leaflet                           | 26/01/2006 | 28/02/2006 | SmPC and PL |                                                                           |
| I1/0048 | UpdateofSummaryofProductCharacteristicsand Package Leaflet                           | 26/01/2006 | 28/02/2006 | SmPC and PL |                                                                           |
| II/0045 | Quality changes                                                                      | 17/11/2005 | 23/12/2005 | SmPC        |                                                                           |
| S/0046  | Annual re-assessment.                                                                | 17/11/2005 | 21/11/2005 |             | Basedon thedatasubmitted theproductremainsunder exceptionalcircumstances. |
| IB/0047 | IB_42_a_01_Changein shelf-lifeoffinishedproduct -aspackagedforsale                   | 07/10/2005 | n/a        | SmPC        |                                                                           |
| I1/0043 | UpdateofSummaryofProductCharacteristicsand                                           | 23/06/2005 | 24/08/2005 | SmPC and PL | The MAH applied to update sections 4.2, 4.4, 4.8, 5.2 and                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Package Leaflet   |
|-------------------|

<div style=\"page-break-after: always\"></div>

|         |                                                                                                 |            |            |          | Section 4.8 Undesirable effects: -Data on9 surgerypatientsfromprotocolC9417-21were addedto theinhibitordevelopmentparagraphinsection 4.8 of the SPC. A total of 10 patients were enrolled in this protocol,but one wascarried over toprotocolC9408-21 andisthereforealreadycoveredbythecurrentstatement in theSPC.These9patients meet thesame criteria as the 56already included in this statement,but noone developed inhibitor antibodies to BeneFIX during or after surgery. -In studies C9417-21 and C9408-21four PTPs experienced a total of 5 e   |
|---------|-------------------------------------------------------------------------------------------------|------------|------------|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0044 | IA_43_a_01_ Add./replacement/del. of measuring or administrationdevice-additionorreplacement    | 27/06/2005 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| I1/0039 | Change(s)to themanufacturingprocessforthe activesubstance                                       | 16/03/2005 | 01/04/2005 |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IB/0042 | IB_42_a_01_Changein shelf-life of finishedproduct - as packaged for sale                        | 23/02/2005 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IA/0040 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph.Eur.cert.avail.) | 11/11/2004 | n/a        | Annex II |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| S/0038  | 7th annual re-assessment                                                                        | 21/10/2004 | 21/10/2004 |          | Basedonthereviewof all availableinformation,theCHMP is of the view that the quality, safety and efficacy of this medicinal productcontinues tobe adequately and sufficientlydemonstrated and thereforeconsidersthatthe benefit/riskprofileofBeneFIXremainsfavourableinthe treatmentofhaemophiliaB.Nonetheless,it is recommendedthatthemarketingauthorisationremains                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                          |            |            |          | underexceptionalcircumstancesuntilthedatarequested- the new PTP study, the PUP study and the post-marketing surveillance of all newpatients inEurope-are available and assessed(seeS/0022).Noupdating of theSPCorthe PLisrequired aspart of thisAnnual Reassessment.                                                                                                                                                                                                                                                                           |
|---------|----------------------------------------------------------------------------------------------------------|------------|------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0032  | 6thAnnualReassessment                                                                                    | 26/02/2004 | 18/08/2004 | Annex II | Basedonthereviewofallavailableinformation,theCHMP is of the view that the quality, safety and efficacy of this medicinal product continues to be adequately and sufficientlydemonstratedandthereforeconsidersthatthe benefit/riskprofileofBeneFIXremainsfavourableinthe treatment ofhaemophiliaB.Nonetheless,it is recommendedthatthemarketingauthorisationremains underexceptionalcircumstancesuntil thedatarequested are available and assessed(seeS/0022).No updating of the SPC or the PL is required as part of this Annual Reassessment. |
| I1/0035 | Change(s) to the test method(s) and/or specificationsfortheactivesubstance                               | 29/07/2004 | 04/08/2004 |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IA/0036 | IA_05_Change in thename and/or addressof a manufacturer of thefinishedproduct                            | 26/07/2004 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| I1/0033 | Quality changes Quality changes                                                                          | 26/02/2004 | 05/03/2004 |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 1/0034  | Extensionofshelf-lifeorretestperiodoftheactive substance 20a_Extension of shelf-lifeorretestperiodof the | 03/11/2003 | 10/11/2003 |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|         | activesubstance                                                      |            |            |                                  |                                                                                                                                                                                                                                           |
|---------|----------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I1/0029 | Quality changes                                                      | 24/07/2003 | 04/11/2003 |                                  |                                                                                                                                                                                                                                           |
| 11/0031 | Change(s) to container Change(s) to shelf-life or storage conditions | 25/09/2003 | 02/10/2003 |                                  | Alternate diluent stopper and extension of the shelf life for the5mldiluentsterilewaterforinjectionsfrom18months to 24 months.                                                                                                            |
| T/0030  | Transfer of Marketing Authorisation                                  | 21/07/2003 | 16/09/2003 | SmPC, Labelling and PL           | TheMAHappliedforthetransferof theMarketing Authorisation of BeneFIXfrom Genetics Institute of Europe B.V.to Wyeth Europa Ltd.                                                                                                             |
| R/0024  | Renewal of the marketing authorisation.                              | 27/06/2002 | 03/02/2003 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                           |
| I1/0027 | Change(s)to container                                                | 21/11/2002 | 27/11/2002 |                                  |                                                                                                                                                                                                                                           |
| 1/0028  | 26_Changestocomplywithsupplementsto pharmacopoeias                   | 15/11/2002 | 19/11/2002 |                                  |                                                                                                                                                                                                                                           |
| I1/0025 | Change(s)to shelf-lifeorstorage conditions                           | 17/10/2002 | 28/10/2002 |                                  |                                                                                                                                                                                                                                           |
| 1/0026  | 26_Changes to comply with supplements to pharmacopoeias              | 06/09/2002 | 24/09/2002 |                                  |                                                                                                                                                                                                                                           |
| 1/0023  | 16_Changeinthebatchsizeoffinishedproduct                             | 27/06/2002 | 03/07/2002 |                                  |                                                                                                                                                                                                                                           |
| II/0021 | UpdateofSummaryofProductCharacteristicsand PackageLeaflet            | 20/09/2001 | 05/02/2002 | SmPC and PL                      | TheMAHappliedforavariationtointroducerelevant informationintheSPCandPL inordertoalign theSPCfor BeneFIXwith thecore CHMPSPCfor\"HumanPlasma- Derived andRecombinantCoagulationFactorIXProducts\" (CPMP/BPWG/1625/99),whichwaspartoftheMAH's |

<div style=\"page-break-after: always\"></div>

| commitmentsfrom the3rdAnnualReassessment.This alignmentexerciseentailsextensivechangestosections 4.1,4.2,4.4,4.8,and 5.2,and minor changes to sections 2,4.3,4.5,4.6,4.9,5.1,5.3,6.2,6.4,6.5and6.6.  Themainchangesimplementedasaresultofthisvariation are:  4.1 Therapeutic indications: The current indication has been modified tobein accordance with the coreSPC,which referstoprophylaxisinsurgicalandnon-surgicalsettings. Theinformationregardingtreatmentofpatientswith inhibitorisalreadycoveredundersection4.2.  4.2Posologyandmethodof administration:Thewordingon dosage recommendations(amount and frequency)has beensimplifiedtoemphasise thedependenceon theclinical effectiveness in each individual.The different ways of expressing Factor IX activity in plasma and the definition of an IU have been inserted in the SPC. The current dosing table for patients with bleeding episodes and/or surgery hasbeenreplacedwiththetableinthecoreSPC.A sentencestating that thereisinsufficientdata to recommendBeneFIXin childrenunder 6hasbeenincluded. AnewrecommendationtoswitchpatientstoanotherFIX product if doses&gt;100IU/kghavebeenrepeatedlyneeded during routine prophylaxis or treatment, even if an inhibitor is not detected,has been included.The information on inhibitorshasbeensimplifiedandarecommendation to consider alternative therapies inpatientswith high inhibitor titresincluded.A number of minor deviationsfrom thecore SPC proposed by the MAH in this section are considered   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|        |                        |            |            | acceptable. 4.4Specialwarnings andspecialprecautionsforuse: Statementsregardingthelackofestablishedsafetyand efficacy in                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|--------|------------------------|------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0022 | 4thannualre-assessment | 15/11/2001 | 23/01/2002 | TheMAHhasconductedseveral studies toinvestigate the cause for the observed RBC agglutination. The low ionic strength,the mostprobable cause ofRBCagglutination,is consideredaqualitydefectofBeneFIX.Asanoutcomeof theseinvestigationstheMAHhascommittedtoreformulate theproductwithin agreed timeframesin ordertoreduce the incidenceofRBC agglutination(see alsoII/0015& S/0016). The CHMP has recommended intensive post-marketing surveillanceforall newpatientstreated withBeneFIX as wellastheinitiationoftwonewstudies.TheCHMPmade thisrecommendationbecauseGCPinspectionsoftwoof the three pivotal clinical studies, on which the Marketing Authorisationisbased，revealed deficiencies,whichraise doubts on the reliability of the clinical data (see also S/0016).Anindependent audit of the three clinical studies, commissioned by Genetics Institute, confirmed the GCP deficiencies,butfound the data toberepresentative of the patient population studied. BeneFIXhasbeencommerciallyavailableintheUnited Statessince1997andintheEUsince1999.Post- marketingdataaccumulatedsincethenfromphysicians treating haemophilia B patients support the safety and efficacyprofileofBeneFIX.TheCHMPconsidersthatthe |

<div style=\"page-break-after: always\"></div>

|         |                                                                 |            |            |             | benefit/riskbalanceofBeneFIXforthetreatmentany prophylaxis of bleeding in previously treated patients (PTPs)withhaemophiliaBremainspositive,basaedon the datapresently available.However,thedataareinsufficient tobecertainofthefrequencyofsomeadversedrug reactions,especiallythoselinkedtoinhibitorformation and to allergicreactions.Inviewof this,there is a needfor enhancedsurveillanceofnewpatientsreceivingBeneFIX. This intensive post-marketinig surveillance will include a reqistryfor all newpatients treatedwithBeneFIX in Europe,andincludecarefulmonitoringfor adverse drug reactions. Patients already treated with BeneFIX may continuetheirtherapy,however,pa   |
|---------|-----------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11/0018 | Update of or change(s) to the pharmaceutical documentation      | 23/08/2001 | 25/10/2001 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| I1/0020 | Quality changes                                                 | 26/07/2001 | 01/08/2001 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 1/0019  | 12_Minor change of manufacturing process of the activesubstance | 26/04/2001 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 11/0017 | UpdateofSummaryofProductCharacteristicsand Package Leaflet      | 14/12/2000 | 23/04/2001 | SmPC and PL | TheMAH appliedfor avariation to introduceintheSPCand PL relevant information to address thepotentially life- threateningallergicreactionsreportedbytheMAHinthe 5th PSUR. Five reports of anaphylactic/ allergic reactions were notified in the reporting interval for the 5th PSuR. Three of these fivesuspected allergicreactionswerepotentiallylife threatening andwere consideredasclassIlIallergic                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         |                                                           |            |            |                        | reactions by the CHMP. The aetiology of the allergic reactions is atpresent unknown.Although allergicreactions afteradministrationofplasmaderivedFactorIXarerarely associatedwithinhibitorformation,itisnotknownwhether patients who experience allergic reactions after treatment withBeneFIXareatincreasedriskofinhibitor development.Duetotheseverityofthereactionsaswell as the unknown aetiology, relevant information has been included in the SPC-sections 4.4 and 4.8-and the PL, to address the potentially life-threatening allergicreactions reported.                                                                                                                                                                                                                                                                                                                                                |
|---------|-----------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I1/0015 | UpdateofSummaryofProductCharacteristicsand PackageLeaflet | 16/11/2000 | 23/04/2001 | SmPC, Labelling and PL | TheMAHappliedforavariationtointroducerelevant informationin theSPC andPLon theredbloodcell agglutination phenomenon that had been observed during administration ofBeneFIX.Inaddition,the address of the MAHhasbeen modified and theSPC,PL andlabelling amended accordingly.Finally modifications in the instructions to reconstitute and administer the product have been introduced in the PL. Five cases of red cell agglutination-occurring in the line of the tubing and theinfusion syringe containingreconstituted BeneFIXandpatient'sblood-werereported in2000and six similar cases were reported in 1997. Following theevaluationoftheclinicalcasesanddatafrom invitrostudiesperformedtoinvestigatethephenomenon ofred cell agglutination(seealsoS/0022),the CHMP concluded that: - these agglutinates form in the vehicle alone and in non- anticoagulated blood or blood anticoagulated with heparin, |

<div style=\"page-break-after: always\"></div>

|        |                          |            |            |          | EDTA orsodium citrate;  - the agglutinates remain quite stable and resistant to dissolution even under venous flow shear rate forces; -in asituation wherered cell agglutinateswere not permitted to form in the syringe prior to injection, fewer andmuchshorterredcellaggregateswereobserved. No clinicalsequelaehavebeenreported in associationwith this observation.If agglutination of redblood cells in the tubing/syringe is observed, all this material (tubing, syringe andBeneFIXsolution)shouldbediscarded and administrationwithanewpackageresumed.                                                                                                                                                                                                                                                                                                                                                                     |
|--------|--------------------------|------------|------------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0016 | 3rd annualre-assessment. | 25/01/2001 | 25/01/2001 | Annex II | Anaphylactic/allergicreactions,inhibitordevelopment, thrombogenicityandhaemorrhage/lackofeffectremain areas of relevance.In mostcasesofallergicreaction no data oninhibitor development are available.Post- marketing studies to evaluate the aetiology of allergic events including anaphylaxis were initiated in 1999. One thromboticeventhasbeenreported afterthedatalock point for the 5th PsUR as well as several cases of bleeding and/or lack of effect. It is apparent that the doses of BeneFIXrequiredwereevenhigherthanthosecalculated, taking theknowndifferenceinrecoveryofBeneFIXinto account. All in all, twelve cases of redcell agglutinationin the syringe/tubing system have been reported. The preliminary datasuggestthatredbloodcell agglutinationiscausedby theBeneFIXvehicleandoccurnotonlyinvitrobutalso whenBeneFIX is injected intotheflowingblood.Suitable measureswill dependonthefinalassessmentofthe |

<div style=\"page-break-after: always\"></div>

|        |                                                                                     |            |            |          | complete data asrequested from theMAH(see also I1/0015&S/0022). There isno evidence ofviral transmissionforHIV and hepatitisA,B,orC as aresult of rFIXtreatment. Since the 3rd annual re-assessment, a GCP inspection has beenperformed.Thisinspection(Sept2000)wasrelated to thePUP study(C9418-21)and the CHMPconcluded in December20o0 thatthisstudywasinvalidforregulatory purposes. As a result, the CHMP requested an inspection of the PTP studies(C9407-21 and 49408-21),tobe carried outfromJan-March2001(seealsoS/0022). TheCHMP,havingreviewedtheevidenceofcompliance withtheSpecificObligationssubmittedbytheMAH and havingre-assessedthebenefit/riskprofileofthemedicinal product,recommendedthatnoamendmentsoftheSPCor PLarenecessaryandthatthemarketing authorisation remainsunderexceptional circumstances.   |
|--------|-------------------------------------------------------------------------------------|------------|------------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0013 | Annual re-assessment.                                                               | 18/11/1999 | n/a        | Annex II |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1/0012 | 17_Changeinspecificationofthemedicinalproduct                                       | 30/06/1999 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1/0011 | 14_Changeinspecificationsofactivesubstance                                          | 30/06/1999 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| S/0009 | Annualre-assessment.                                                                | 19/11/1998 | 29/03/1999 | Annex II |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| N/0010 | Minorchangeinlabellingorpackageleafletnot connectedwiththeSPC(Art.61.3Notification) | 22/02/1999 | 08/04/1999 | PL       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| 1/0004   | 03_Changeinthename and/or addressof the marketing authorisationholder   | 26/10/1998   | 11/01/1999   | SmPC, Labelling and PL   |                        |
|----------|-------------------------------------------------------------------------|--------------|--------------|--------------------------|------------------------|
|          | 14_Changeinspecificationsofactive substance                             | 08/12/1998   | n/a          |                          | 1/0007                 |
|          | 17_Change in specification of the medicinal product                     | 08/12/1998   | n/a          |                          | 1/0006                 |
|          | 17_Change in specification of the medicinal product                     | 08/12/1998   | n/a          |                          | 1/0005                 |
|          | UpdateofSummaryofProductCharacteristicsand                              | 23/07/1998   | 11/11/1998   | SmPC,  Labelling and PL  | II/0003 PackageLeaflet |
|          | 14_Changein specificationsof active substance                           | 09/10/1998   | n/a          |                          | 1/0008                 |
|          | 01_Changefollowing modification(s)of the manufacturing authorisation(s) | 22/04/1998   | n/a          |                          | 1/0001                 |